@Article{096504019X15755437099308,
AUTHOR = {Stefania Nobili, Daniele Lavacchi, Gabriele Perrone, Giulio Vicini, Renato Tassi, Ida Landini, 
AnnaMaria Grosso, Giandomenico Roviello, Roberto Mazzanti, Carmine Santomaggio, Enrico Mini},
TITLE = {Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data  From a Single-Institution Experience},
JOURNAL = {Oncology Research},
VOLUME = {28},
YEAR = {2020},
NUMBER = {3},
PAGES = {237--248},
URL = {http://www.techscience.com/or/v28n3/48529},
ISSN = {1555-3906},
ABSTRACT = {The use of vinorelbine as a single agent or in combination regimens in non-small cell lung cancer (NSCLC) is 
associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectable or metastatic NSCLC patients, according to real-world treatment patterns, has 
still not been widely explored. Eighty-one patients treated at a single institution were retrospectively analyzed. 
Thirty-seven received standard first-line single-agent vinorelbine, and 44 received vinorelbine plus platinum 
drugs, based on physician’s choice; 61.7% were older than 70 years, and 60.5% were affected by 2 comorbidities. Sixty-three patients were evaluable for objective response: 22% achieved partial response and 41% stable 
disease. Median progression-free survival (PFS) was 5.4 months. A benefit in PFS was observed in patients 
treated with combinations vs. single-agent vinorelbine (6.7 vs. 3.5 months, <i>p</i>=0.043). Median overall survival 
(OS) was 10.4 months without a statistically significant difference between treatments (12.4 vs. 7.5 months). 
In 55 stage IV patients, OS was positively correlated with combination regimens, M1a stage, or 2 metastatic 
lesions. Grade 3–4 toxicity occurred in 33% of patients, and dose reduction in 11%. A statistically significant 
higher incidence of toxicity was observed in patients receiving combinations, in women, in patients younger 
than 75 years, or patients with metastases. In this real-word analysis, we confirmed the efficacy and tolerability 
of vinorelbine as a single agent or combined with platinums in patients usually underrepresented in controlled 
clinical trials. Single-agent vinorelbine may represent a suitable option in elderly or unfit NSCLC patients and 
warrants investigation as a potential drug candidate for immunochemotherapy combination regimens.},
DOI = {10.3727/096504019X15755437099308}
}